Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label leniolisib study in Japanese patients with APDS followed by long-term extension
jRCT2061230036Active, not recruiting
- Sponsor
- Pharming Group
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of leniolisib in Activated PI3Kδ syndrome (APDS), sponsored by Pharming Group. Primary endpoints: Part 1 - Treatment-emergent adverse events, Part 1 - Laboratory safety parameters and 10 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
leniolisib
03
Conditions
Activated PI3Kδ syndrome (APDS)
Beyond the preview
Go deeper on jRCT2061230036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230036.